Prof. Raal presents a case of a 16-year old female with homozygous familial hypercholesterolemia (HoFH) and discusses the cumulative LDL-c lowering effects of different therapies in this patient.

A pooled analysis showed that calculating the average LDL-c concentration over a longer period of time demonstrated a larger LDL-c reduction by evolocumab in FH patients.

Prof. Stroes explains that combination therapy holds the promise to achieve LDL-c target levels in patients with homozygous familial hypercholesterolemia (HoFH).

Homozygous familial hypercholesterolemia (HoFH) is a genetic condition that is associated with very high levels of LDL-c from birth. Prof. Ray shows how outcomes can be improved by earlier diagnosis and use of multiple lipid-lowering treatments.

EAS 2022 Kanika Dharmayat talks about how to achieve early identification of FH patients based on findings from an analysis of the EAS FHSC global registry on children and adolescents with FH.

EAS 2022 Data on characteristics of FH in children are critical to inform contemporary approaches to identify children/adolescents with FH worldwide.

In a follow-up study of the CLEAR Harmony trial, up to 2.5 years of continuous treatment with bempedoic acid was generally well tolerated and stably decreased LDL-c levels in patients with ASCVD and/or heterozygous familial hypercholesterolemia.

There is a need for robust aggregated data on homozygous FH (HoFH). Tycho Tromp shares the first results of a study on a unique worldwide cohort of HoFH patients.

The FDA has approved the small interfering RNA (siRNA) PCKS9 therapy inclisiran to lower LDL-c with two doses a year, after a first dose and one at 3 months, for treatment of adults with clinical ASCVD or FH.

A cost-effectiveness study suggests that population genomic screening for FH in young adults could be cost-effective from a healthcare perspective and cost-saving from a societal perspective at testing costs that are feasible.

This study investigated the prevalence and impact of monogenic FH and clinically defined FH in a large proportion of the Icelandic population.

This study investigated the duration of pregnancy-related off-statin periods in Norwegian and Dutch women with FH. Among these women, 86% wanted to receive more information on pregnancy and breastfeeding in relation to FH.